Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative ColitisDahham Alsoud, Bram Verstockt, Gert De Hertogh et al.|Journal of Crohn s and Colitis|2022Cited by 27
Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab ConcentrationsNathalie Van den Berghe, Debby Thomas, Bram Verstockt et al.|Journal of Crohn s and Colitis|2020Cited by 15
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseasesWannee Kantasiripitak, Erwin Dreesen, Bram Verstockt et al.|British Journal of Clinical Pharmacology|2021Cited by 14
Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn’s DiseaseNathalie Van den Berghe, Paul Declerck, Bram Verstockt et al.|Clinical Gastroenterology and Hepatology|2021Cited by 7
Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s diseaseNathalie Van den Berghe, Debby Thomas, Dahham Alsoud et al.|Therapeutic Advances in Gastroenterology|2023Cited by 7